20/20 Biolabs jumps on Ebola, hantavirus testing plans

Statera Biopharma

22/05/2026 14:11

** Shares of diagnostics firms 20/20 Biolabs AIDX.O rise 20% to $1.49 premarket

** Co says it is preparing plans to offer Ebola and hantavirus testing if public health agencies need support

** Co is leveraging its COVID-19 testing experience to expand into these infectious disease tests

** AIDX cautioned that no test is ready yet and that regulatory approval would still be required before any test could be used clinically

** As of last close, AIDX down ~95% since its Nasdaq debut on February 19

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))